Abstract: A polymer of formula (I) where X1 and X2 respectively represent the alpha and omega end groups of the polymer; R1 represents a hydrogen atom or a straight or branched chain alkyl group; R2 represents a straight or branched chain alkyl group which is substituted by a group which may have a positive charge at physiological pH; and n represents the number of repetitive units of the polymer, or a copolymer thereof; for use as a medicament and for treatment of a heparin overdose wherein the polymer of formula (I) has been found to have a selectivity and affinity for heparin.

Abstract: A hydrogel bead for intra-articular supplement made by: providing a solution of alginate, providing a solution with chitosan having a Mw between lower than 60 kD, mixing the solution of alginate and the solution of chitosan, wherein the mixed solution comprises between 0.5 and 0.7% (w/v) of chitosan and between 1 and 1.4% alginate (w/v), introducing droplets of the mixed solution into a solution with Ca2+ or Sr2+ cations and isolating polymerised beads from the solution with cations.

Abstract: A compound of formula (I-1) wherein n equals 0 or 1, Z represents O or S, R1 represents one group chosen among the group consisting of hydrogen, C1-C7 alkyl, substituted, or not, by a halogen, a hydroxyl or a —O—R12 group, wherein R12 is a C1-C7 alkyl, a group —CH2—O—CO—R5 wherein R5 is chosen among a hydrogen atom and a C1-C7 alkyl, substituted or not by at least one halogen, a group —O—R13, wherein R13 is chosen among hydrogen and a C1-C7 alkyl, an amine or a —CH2-amine, R?1 represents a group chosen among hydrogen and —O—R14, wherein R14 is chosen among hydrogen and a C1-C7 alkyl, and R2 is chosen among the group consisting of a C1-C7 alkyl, a C3-C6 cycloalkyl, an aryl group, and an heteroaryl group for the treatment of pathologies involving excess activity of at least one member of the kallikrein family.

Abstract: The present invention relates to a hydrogel matrix comprising cartilage-forming cells wherein alginate, chitosan and cartilage-forming cells are mixed and subsequently polymerized into beads.

Abstract: A polymer of formula (I) where X1 and X2 respectively represent the alpha and omega end groups of the polymer; R1 represents a hydrogen atom or a straight or branched chain alkyl group; R2 represents a straight or branched chain alkyl group which is substituted by a group which may have a positive charge at physiological pH; and n represents the number of repetitive units of the polymer, or a copolymer thereof; for use as a medicament and for treatment of a heparin overdose wherein the polymer of formula (I) has been found to have a selectivity and affinity for heparin.

Abstract: The invention relates to the prophylactic and therapeutic applications of certain estrogenic components, such as estetrol, in neurological disorders, such as neonatal hypoxic-ischemic encephalopathy (HIE).

Abstract: A transobturator technique was developed for treating male urinary incontinence. This approach helped to design specific instruments to pass around the ischio-pubic branches of the male pelvis from inside to outside (i.e from the suburethral space to the thigh fold). The inside-out transobturator sling technique uses specific instruments and a polypropylene mesh with two arms that are passed inside to outside through the obturator foramens, pulled for compressing the bulbar urethra upward, and tied to each other across the midline. The mesh passes around the ischio-pubic branch before being tied under the bulbar urethra where it brings tension and support.

Abstract: A method can be used for treating or reducing likelihood of an influenza A virus-induced disease in a mammal. The method includes administering a polynucleotide to the mammal. Theis polynucleotide includes a gene encoding Mx protein having a TRAF2 and/or a TRAF6 binding domain. The TRAF2 and/or TRAF6 binding domain can be represented by the sequences P-X-Q/E-E, P-X-Q/E-X-X-D, or P-X-E-E-X-E. The TRAF2 and/or TRAF6 binding domain can also be located in the Mx protein in a position which corresponds to the position of the hexapeptide PEEESE in the bovine Mx1 protein or in a position which is up to 20 amino acid residues upstream or downstream of that position.

Abstract: The present invention provides MT4-MMP inhibitor and EGFR inhibitor for use in the treatment of cancer, wherein said MT4-MMP inhibitor and EGFR inhibitor are different from each other. MT4-MMP (MMP-17) is a glycosylphosphatidyl inositol (GPI) anchored MMP produced by cancer cells that promotes tumor vascularization and metastases. The present invention found that MT4-MMP expression promotes cancer cell proliferation. These effects involve retinoblastoma protein (Rb) inactivation, cyclin dependent kinase CDK4 activation and Epidermal Growth Factor Receptor (EGFR) signaling. Co-immuno-precipitations indicate the existence of protein complexes harboring MT4-MMP and EGFR. The present invention further found a novel mechanism of MT4-MMP action through an outside-in signaling involving EGFR. An unexpected crosstalk between an MMP and EGFR was identified and recognized as a key driver of cancer cell biology.

Abstract: The invention relates to the identification of a biomarker whose abundance in biological sample is changed in subjects with osteoarthritis and/or other ageing-related diseases. The biomarker has applications in the diagnosis of osteoarthritis and/or other ageing-related diseases, in determining the prognosis for an individual diagnosed with osteoarthritis and/or other ageing-related diseases, and in monitoring the efficacy of treatment for osteoarthritis and/or other ageing-related diseases.

Abstract: The invention provides the use of a cyclodextrin compound for the manufacturing of a medicament for the treatment or prevention of bronchial inflammatory diseases, particularly for asthma and chronic obstructive pulmonary disease (COPD).

Abstract: A compound of formula (I-1) wherein n equals 0 or 1, Z represents O or S, R1 represents one group chosen among the group consisting of hydrogen, C1-C7 alkyl, substituted, or not, by a halogen, a hydroxyl or a —O—R12 group, wherein R12 is a C1-C7 alkyl, a group —CH2—O—CO—R5 wherein R5 is chosen among a hydrogen atom and a C1-C7 alkyl, substituted or not by at least one halogen, a group —O—R13, wherein R13 is chosen among hydrogen and a C1-C7 alkyl, an amine or a —CH2— amine, R?1 represents a group chosen among hydrogen and —O—R14, wherein R14 is chosen among hydrogen and a C1-C7 alkyl, and R2 is chosen among the group consisting of a C1-C7 alkyl, a C3-C6 cycloalkyl, an aryl group, and an heteroaryl group for the treatment of pathologies involving excess activity of at least one member of the kallikrein family.

Abstract: An object of the present invention is to provide a cheap, rapid, controlled, reproducible and polyvalent method for manufacturing a light emitting device with an internal source of light capable of achieving an enhancement in extraction efficiency. The invention proposes a method for manufacturing an optical layer for a light emitting device having an internal source of light and an optical layer separating the internal source of light and an external medium of light diffusion, wherein the method comprises the use of coherent electromagnetic radiation speckle lithography, such as laser speckle lithography, to make a nano/micro texturation on at least one surface of the optical layer.

Abstract: The present invention relates to a patient immobilisation device for positioning a patient in the prone position for breast irradiation, comprising a cephalic module for supporting the head and upper extremities of the patient, a thoracic module for supporting the patient thorax, and shaped to allow at least one breast to extend below the thoracic module, and a caudal module for supporting the pelvis and lower extremities of the patient, wherein the cephalic module is optionally detachable and securable to the thoracic module; wherein the thoracic module is optionally detachable and securable to the caudal module and the device can be pivoted in an indexed way around a craniocaucal patient axis F.

Abstract: Disclosed is a system and device for observation of an eye (E) comprising a light source (LSo) for illuminating the eye. Further, the system includes a diffraction grating as an optical relay (OR) for receiving the light reflected from the eye and for deflecting it towards a light sensor (LSe). The incident light ray (r inc) intersects the optical relay at an incidence angle (alphajnc) with the normal (n_OR) to the optical relay in an incidence plane (Pl_inc) formed by the incident light ray (r_inc) and the normal (n_OR). The deflected light ray (r def) forms a deflection angle (alpha def) with the normal (n_OR) in a deflection plane (Pl def) formed by the deflected light ray (r_def) and the normal (n_OR). The optical relay is positioned such that the incidence and the deflection angle and/or the incidence plane and the deflection plane are different from each other.

Abstract: A method of producing a hydrogel for intra-articular supplement comprising the steps of: providing a solution of alginate, providing a solution with chitosan having a Mw between lower than 60 kD, mixing the solution of alginate and the solution of chitosan, wherein the mixed solution comprises between 0.5 and 0.7% (w/v) of chitosan and between 1 and 1.4% alginate (w/v), introducing droplets of the mixed solution into a solution with Ca2+ or Sr2+ cations and isolating polymerized beads from the solution with cations.

Abstract: The present invention relates to a method of producing a hydrogel matrix comprising cartilage-forming cells wherein alginate, chitosan and cartilage-forming cells are mixed and subsequently polymerized into beads.

Abstract: The present invention relates to a portable industrial instrument for performing, in an integrated and two-way manner, an interferometric fringe projection and shearography, on a object to be tested, so that, when the two-way interferometer (1) is associated with the coherent or quasi-coherent projection device (2), the instrument is able to measure the 3D shape of the object by interferometric fringe projection, also known as moiré method, and, when the two-way interferometer (1) is associated with the recording or imaging device (4), the instrument is able to perform shearographic measurements on the object, the direction of the traversing light beam in the interferometer (1) being reversed when shifting from one measurement configuration to the other one.

Abstract: The present invention relates to methods for determining the concentration of a free beta-lactam antibiotic in a biological sample. In particular, the present invention relates to methods for measuring a free beta-lactam antibiotic in a biological sample, comprising the steps of: (a) providing at least one class C beta-lactamase, a functional fragment or variant thereof; (b) providing at least one biological sample; (c) contacting said at least one class C beta-lactamase with said at least one biological sample; and (d) determining the concentration of said free beta-lactam antibiotic in said at least one biological sample.

Abstract: The application teaches a composition comprising one or more pharmaceutical active ingredients selected from the group consisting of interleukin-8 (IL-8 or CXCL8), a functional fragment of IL-8, a functional variant of IL-8, and an agonist of IL-8 receptor, for therapeutic and/orprophylactic interventions in impaired bone fracture healing, such as but not limited to non-union fractures, mal-union fractures, or delayed union fractures.